291 related articles for article (PubMed ID: 28838715)
1. Abscopal Effect of Nivolumab in a Patient with Primary Lung Cancer.
Komatsu T; Nakamura K; Kawase A
J Thorac Oncol; 2017 Sep; 12(9):e143-e144. PubMed ID: 28838715
[No Abstract] [Full Text] [Related]
2. Liver Metastasis Is Associated with Poor Progression-Free Survival in Patients with Non-Small Cell Lung Cancer Treated with Nivolumab.
Funazo T; Nomizo T; Kim YH
J Thorac Oncol; 2017 Sep; 12(9):e140-e141. PubMed ID: 28838713
[No Abstract] [Full Text] [Related]
3. A Case of a Patient with Idiopathic Pulmonary Fibrosis with Lung Squamous Cell Carcinoma Treated with Nivolumab.
Khunger M; Velcheti V
J Thorac Oncol; 2017 Jul; 12(7):e96-e97. PubMed ID: 28629548
[No Abstract] [Full Text] [Related]
4. Durable response to nivolumab in a lung adenocarcinoma patient with idiopathic pulmonary fibrosis.
Ide M; Tanaka K; Sunami S; Asoh T; Maeyama T; Tsuruta N; Nakanishi Y; Okamoto I
Thorac Cancer; 2018 Nov; 9(11):1519-1521. PubMed ID: 30152594
[TBL] [Abstract][Full Text] [Related]
5. Neutrophil-to-lymphocyte ratio after four weeks of nivolumab administration as a predictive marker in patients with pretreated non-small-cell lung cancer.
Takeda T; Takeuchi M; Saitoh M; Takeda S
Thorac Cancer; 2018 Oct; 9(10):1291-1299. PubMed ID: 30126063
[TBL] [Abstract][Full Text] [Related]
6. Nivolumab improves survival for patients with advanced lung cancer.
Printz C
Cancer; 2017 Sep; 123(17):3211. PubMed ID: 28833027
[No Abstract] [Full Text] [Related]
7. Nivolumab (Opdivo°) and metastatic or inoperable lung cancer.
Prescrire Int; 2017 Apr; 26(181):93-94. PubMed ID: 30730658
[No Abstract] [Full Text] [Related]
8. Bullous pemphigoid and nivolumab: Dermatologic management to support and continue oncologic therapy.
Panariello L; Fattore D; Annunziata MC; Piantedosi F; Gilli M; Fabbrocini G
Eur J Cancer; 2018 Nov; 103():284-286. PubMed ID: 30268391
[No Abstract] [Full Text] [Related]
9. Serial Troponin for Early Detection of Nivolumab Cardiotoxicity in Advanced Non-Small Cell Lung Cancer Patients.
Sarocchi M; Grossi F; Arboscello E; Bellodi A; Genova C; Dal Bello MG; Rijavec E; Barletta G; Rossi G; Biello F; Ghigliotti G; Canepa M; Mussap M; Brunelli C; Spallarossa P
Oncologist; 2018 Aug; 23(8):936-942. PubMed ID: 29567824
[TBL] [Abstract][Full Text] [Related]
10. Resolution of remitting seronegative symmetrical synovitis with pitting edema (RS3PE) during Nivolumab therapy for non-small cell lung cancer: a case report.
Filetti M; Anselmi E; Macrini S; Rizzo F; Iacono D; Giusti R; Marchetti P
Semin Arthritis Rheum; 2018 Oct; 48(2):e17-e20. PubMed ID: 29402438
[No Abstract] [Full Text] [Related]
11. Successful treatment with nivolumab for lung cancer with low expression of PD-L1 and prominent tumor-infiltrating B cells and immunoglobulin G.
Suyama T; Fukuda Y; Soda H; Ogawara D; Iwasaki K; Hara T; Yoshida M; Harada T; Umemura A; Yamaguchi H; Mukae H
Thorac Cancer; 2018 Jun; 9(6):750-753. PubMed ID: 29667757
[TBL] [Abstract][Full Text] [Related]
12. Central Nervous System Pseudoprogression With Nivolumab in a Patient With Squamous Cell Lung Cancer Followed by Prolonged Response.
Swami U; Smith M; Zhang J
J Thorac Oncol; 2018 Sep; 13(9):e183-e184. PubMed ID: 30166022
[No Abstract] [Full Text] [Related]
13. Early Use of Systemic Corticosteroids in Patients with Advanced NSCLC Treated with Nivolumab.
Scott SC; Pennell NA
J Thorac Oncol; 2018 Nov; 13(11):1771-1775. PubMed ID: 29935305
[TBL] [Abstract][Full Text] [Related]
14. Nivolumab for the treatment of colorectal cancer.
Smith KM; Desai J
Expert Rev Anticancer Ther; 2018 Jul; 18(7):611-618. PubMed ID: 29792730
[TBL] [Abstract][Full Text] [Related]
15. Nivolumab-Associated Guillain-Barre Syndrome in a Patient With Non-Small-Cell Lung Cancer.
Thapa B; Khalid S; Vakili R; Ui J; Misbah S
Am J Ther; 2018; 25(6):e761-e763. PubMed ID: 29889678
[No Abstract] [Full Text] [Related]
16. Drastic decrease of the HIV reservoir in a patient treated with nivolumab for lung cancer.
Guihot A; Marcelin AG; Massiani MA; Samri A; Soulié C; Autran B; Spano JP
Ann Oncol; 2018 Feb; 29(2):517-518. PubMed ID: 29206889
[No Abstract] [Full Text] [Related]
17. Nivolumab in non-small-cell lung cancer with EGFR mutation.
Yoshida H; Kim YH; Ozasa H; Nagai H; Sakamori Y; Tsuji T; Nomizo T; Yasuda Y; Funazo T; Hirai T
Ann Oncol; 2018 Mar; 29(3):777-778. PubMed ID: 29161357
[No Abstract] [Full Text] [Related]
18. Anti-PD-1 Drug (Nivolumab) May Induce Acute and Life-Threatening Pancreatitis in Lung Cancer Patient: A Case Report.
Jiang R; Xu L; Huang Y; Fang C; Guo H; Li S; Wu J; Du Z
Pancreas; 2018 Sep; 47(8):e53-e54. PubMed ID: 30113432
[No Abstract] [Full Text] [Related]
19. Harnessing the PD-1 Pathway in Myelodysplastic Syndrome.
Mukherjee S; Ibrahimi S; Aljumaily R; Cherry M
Am J Ther; 2018; 25(6):e711-e712. PubMed ID: 29394170
[No Abstract] [Full Text] [Related]
20. Intracranial Response to Nivolumab in a Patient with PD-L1-negative Lung Adenocarcinoma.
Nakahara Y; Fukui T; Shirasawa M; Harada S; Kusuhara S; Takakura A; Yokoba M; Mitsufuji H; Kubota M; Katagiri M; Sasaki J; Masuda N; Inukai M; Sekiguchi T; Naoki K
Intern Med; 2018 Nov; 57(21):3149-3152. PubMed ID: 29877291
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]